Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits
Lassa virus can cause haemorrhagic fever for which no specific treatment currently exists. Here the authors have cloned 113 monoclonal antibodies from the survivors of Lassa infection and show that the majority of neutralizing antibodies target a complex of GP1 and GP2 viral proteins.
Guardado en:
Ejemplares similares
-
Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans
por: Rodrigo Borrega, et al.
Publicado: (2021) -
Process optimization and performance evaluation of a downdraft gasifier for energy generation from wood biomass
por: Ilesanmi Daniyan, et al.
Publicado: (2021) -
A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
por: Thomas W. Geisbert, et al.
Publicado: (2021) -
Deep Sequencing Identifies Noncanonical Editing of Ebola and Marburg Virus RNAs in Infected Cells
por: Reed S. Shabman, et al.
Publicado: (2014) -
Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
por: Robert W. Cross, et al.
Publicado: (2020)